Sage Journals: Discover world-class research

Abstract

Introduction:

Phantom limb pain (PLP) is a complex condition resulting in pain in the missing limb affecting 60–80% amputees. Increasing number of patients are undergoing amputations. Approximately 1 per every 1000 people in the United Kingdom is an amputee. Incidence of PLP can be as high as 80% following amputation. PLP can be severe and difficult to treat. A range of pharmacological interventions exist yet little is known about them in respect to PLP. This article will address the effectiveness of both single pharmacological, therapy as well as drug combination therapy.

Methods:

We reviewed all literature looking at the evidence for the efficacy of both single and combined pharmacological therapy in the management of phantom limb pain. Not all commonly prescribed analgesic agents have been studied in the use of PLP and in these cases, the evidence of their efficacy in neuropathic pain was reviewed

Conclusion:

It is difficult to draw definitive conclusions on the pharmacological management of PLP based on current available evidence. Most trials involved small cohorts and were not specific to the PLP. The trials which looked specifically at the PLP population gave conflicting results. Only the N-methyl-d-aspartate (NMDA) receptor antagonist class demonstrated consistent positive results. Most notably ketamine did produce a reduction in pressure pain thresholds and pain windup associated with PLP, although the numbers in these studies remain small. This benefit was not demonstrated across all NMDA receptor antagonists. Combination therapy has demonstrated effectiveness in previous studies for neuropathic pain but this has never been tested specifically against a PLP cohort. Therefore, combination treatment of agents with proven efficacy in PLP such as opioid and gabapentin deserves a closer examination in a controlled study against a placebo as well as single drug therapy

Keywords

Phantom Limb chronic pain pain intractable postoperative

Get full access to this article

View all access options for this article.

References

Ephraim

Wegener

MacKenzie

et al . Phantom pain, residual limb pain, and back pain in amputees: results of a national survey. Arch Phys Med Rehabil 2005; 86(10): 1910–1919.

Norgren

Hiatt

Dormandy

et al . Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45: S5–S67.

Ahmad

Thomas

Gil

et al . Lower limb amputation in England: prevalence, regional variation and relationship with revascularisation, deprivation and risk factors. A retrospective review of hospital data. J R Soc Med 2014; 107(12): 483–489.

Ziegler-Graham

MacKenzie

Ephraim

et al . Estimating the prevalence of limb loss in the United States: 2005 to 2050. Arch Phys Med Rehabil 2008; 89(3): 422–429

Nikolajsen

Jensen

TS.

Phantom limb pain. Br J Anesth 2001; 87(1): 107–16.

Whyte

Carroll

LJ.

A preliminary examination of the relationship between employment, pain and disability in an amputee population. Disabil Rehabil 2002; 24(9): 462–470.

Richardson

Glenn

Nurmikko

et al . Incidence of phantom phenomena including phantom limb pain 6 months after major lower limb amputation in patients with peripheral vascular disease. Clin J Pain 2006; 22(4): 353–358.

Reiber

Mcfarland

Hubbard

et al . Servicemembers and veterans with major traumatic limb loss from Vietnam war and OIF/OEF conflicts: survey methods, participants, and summary findings. J Rehabil Res Dev 2010; 47(4): 275–297.

Bosmans

Geertzen

JHB

Post

et al . Factors associated with phantom limb pain: a 31/2-year prospective study. Clinical Rehabilitation 2010; 24(5): 444–453.

10.

Davidson

Khor

Jones

LE.

A cross-sectional study of post-amputation pain in upper and lower limb amputees, experience of a tertiary referral amputee clinic. Disabil Rehabil 2010; 32(22): 1855–1862.

11.

Desmond

Maclachlan

Prevalence and characteristics of phantom limb pain and residual limb pain in the long term after upper limb amputation. Int J Rehabil Res 2010; 33(3): 279–282.

12.

Dickinson

Head

Gitlow

et al . Maldynia: pathophysiology and management of neuropathic and maladaptive pain – a report of the AMA council on science and public health. Pain Med 2010; 11(11): 1635–1653.

13.

Baron

Mechanisms of disease: neuropathic pain – a clinical perspective. Nat Clin Pract Neurol 2006; 2(2): 95–106

14.

Ramachandran

Brang

McGeoch

PD.

Dynamic reorganization of referred sensations by movements of phantom limbs. NeuroReport 2010; 21(10): 727–730.

15.

Chapman

Neuromatrix theory. J Pain 1996; 5(2), pp.139–142.

16.

Verdu

Decosterd

Buclin

et al . Antidepressants for the treatment of chronic pain. Drugs 2008; 68(18): 2611–2632.

17.

Robinson

Czerniecki

Ehde

et al . Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study. Arch Phys Med Rehabil 2004; 85(1): 1–6.

18.

Redrobe

Bourin

Colombel

et al . Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology 1998; 138(1): 1–8.

19.

Rowbotham

Goli

Junz

et al . Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004; 100: 697–706.

20.

Lunn

Hughes

Wiffen

PJ.

Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev 2014; 1: CD007115.

21.

Shimoyama

Hori

Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain 2000; 85: 405–414.

22.

Jensen

Madsen

Finnerup

NB.

Pharmacology and treatment of neuropathic pains. Curr Opin Neurol 2009; 22(5): 467–474.

23.

Bone

Critchley

Buggy

Gabapentin in postamputation phantom limb pain: a randomized, double-blind, placebo-controlled, cross-over study. Reg Anesth Pain Med 2002; 27(5): 481–486.

24.

Smith

Ehde

Hanley

et al . Efficacy of gabapentin in treating chronic phantom limb and residual limb pain. J Rehabil Res Dev 2005; 42(5): 645–654.

25.

Nikolajsen

Finnerup

Kramp

et al . A randomized study of the effects of gabapentin on postamputation pain. Anesthesiology 2006; 105(5): 1008–1015

26.

Harden

Houle

Remble

et al . Topiramate for phantom limb pain: a time-series analysis. Pain Med 2005; 6(5): 375–378.

27.

Murray

(ed.). Physicians’ desk reference. Montvale, NJ: Thompson PDR, 2004.

28.

Eichenberger

Neff

Sveticic

et al . Chronic phantom limb pain: the effects of calcitonin, ketamine, and their combination on pain and sensory thresholds. Anesth Analg 2008; 106(4): 1265–1273

29.

Jaeger

Maier

Calcitonin in phantom limb pain: a double-blind study. Pain 1992; 48: 21–27

30.

Nikolajsen

Hansen

Nielsen

et al . The effect of ketamine on phantom pain: a central neuropathic disorder maintained by peripheral input. Pain 1996; 67(1): 69–77.

31.

Huse

Larbig

Flor

et al . The effect of opioids on phantom limb pain and cortical reorganization. Pain 2001; 90(1–2): 47–55.

32.

Ben Abraham

Marouani

Kollender

et al . Dextromethorphan for phantom pain attenuation in cancer amputees: a double-blind crossover trial involving three patients. Clin J Pain 2002; 18(5): 282–285.

33.

Wiech

Kiefer

Töpfner

et al . A placebo-controlled randomized crossover trial of the N-methyl-D-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain. Anesth Analg 2004; 98(2): 408–413.

34.

Schley

Topfner

Wiech

et al . Continuous brachial plexus blockade in combination with the NMDA receptor antagonist memantine prevents phantom pain in acute traumatic upper limb amputees. Eur J Pain 2007; 11(3): 299–308.

35.

Weeks

Anderson-Barnes

Tsao

JW.

Phantom limb pain: theories and therapies. Neurologist 2010; 16(5): 277–86.

36.

The Royal College of Anaesthetists. Opioids aware: a resource for patients and healthcare professionals to support prescribing of opioid medicines for pain, 2017, http://www.fpm.ac.uk/faculty-of-pain-medicine/opioids-aware

37.

Tella

Staats

et al . Analgesic effects of intravenous lidocaine and morphine on postamputation pain: a randomized double-blind, active placebo-controlled, crossover trial. Anesthesiology 2002; 96(2): 841–848.

38.

Agarwal

Tella

et al . Morphine versus mexiletine for treatment of postamputation pain: a randomized, placebo-controlled, crossover trial. Anesthesiology 2008; 109(2): 289–296.

39.

Sassano-Higgins

Baron

Juarez

et al . A review of ketamine abuse and diversion. Depress Anxiety 2016; 33(8): 718–727.

40.

Moore

Derry

Aldington

et al . Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev 2015; 7: CD008242.

41.

Moore

Straube

Wiffen

et al . Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009; 3: CD007076.

42.

Chaparro

Wiffen

Moore

et al . Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev 2012; 7: CD008943.

43.

Hanna

O’Brien

Wilson

MC.

Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain 2008; 12: 804–813.

44.

Gilron

Bailey

et al . Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005; 352(13): 1324–1334.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.48 MB

Phantom limb pain: a review of pharmacological management

Abstract

Introduction:

Methods:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material